Featured Research

from universities, journals, and other organizations

HIV's sugar coating offers new vaccine approach

Date:
July 27, 2010
Source:
University of Oxford
Summary:
The chains of sugar molecules, or carbohydrates, that cover the outside of the highly variable HIV virus remain constant, are different from those found on human cells, and could form the basis of a promising new approach to an AIDS vaccine, according to new research.

The chains of sugar molecules, or carbohydrates, that cover the outside of the highly variable HIV virus remain constant, are different from those found on human cells, and could form the basis of a promising new approach to an AIDS vaccine, according to research led by the University of Oxford.

The researchers suggest that a vaccine based on synthetic versions of the HIV carbohydrate coat, because it is so unchanging, could prime the body's immune system to recognise the otherwise rapidly changing HIV virus and fight off any infection.

'We're used to flu vaccines being reformulated every year because new strains come along,' said Dr Chris Scanlan of the Department of Biochemistry at the University of Oxford, who led the research. 'Yet you will see more viral diversity develop in a single HIV patient in a single day than you will in the whole flu season this year across the whole of the UK. That is some challenge for developing a vaccine against HIV.

'We're cautiously optimistic that this research could lead to a promising new approach for a vaccine against HIV/AIDS,' said Dr Scanlan. 'We've found something that doesn't change across all classes of HIV -- from viruses found in the USA to those in Uganda -- and it's something that can be made and manufactured.'

The team from Oxford University, The Scripps Research Institute in La Jolla, California, and the Ragon Institute in Boston, Massachusetts report their findings in the journal Proceedings of the National Academy of Sciences (PNAS).

The researchers were able to isolate the carbohydrate coating from different samples of live HIV-1 virus, representing typical viruses found in different parts of the world, and analyse their chemical structures for the first time. They found that the carbohydrates are unique and are found across all classes or 'clades' of HIV-1. Importantly, these carbohydrates are completely different to the patterns of sugars found on human cells.

The researchers also showed that existing vaccines being developed against HIV will not have the same carbohydrate structures within their formulations as the native HIV virus and so may not mimic this element of the virus adequately.

'The dense cloud of carbohydrates covering the virus has been called its 'carbohydrate camouflage' because the carbohydrate chains look like those on the outside of the body's own cells, and so they aren't normally recognised by the immune system,' explained Dr Scanlan.

'We've shown that HIV's camouflage may be flawed. The carbohydrates on an HIV virus are different to the body's own cells, and that might give us an opportunity to attack.

'It is possible to educate the immune system to these differences. You can include danger signals in your vaccine formulation to force the immune system to take notice of particular carbohydrate structures. Some cancer vaccines in development use this approach, for example,' he added.

The team now aim to come up with ways of making synthetic versions in the lab of the particular carbohydrates found on the outside of HIV. These could then be combined with an adjuvant -- a factor that enhances the body's immune response -- to give a completely new vaccine candidate for evaluation.

The researchers have already shown in their PNAS paper that it is possible to modify a human cell line to produce the gp120 HIV protein with the correct carbohydrates attached. This is one way that the carbohydrates for any future vaccine could be produced.

The research was funded by the International AIDS Vaccine Initiative (IAVI), the Oxford Glycobiology Endowment, the National Institute of Allergy and Infectious Diseases, and the Ragon Institute.


Story Source:

The above story is based on materials provided by University of Oxford. Note: Materials may be edited for content and length.


Journal Reference:

  1. Doores et al. Envelope glycans of immunodeficiency virions are almost entirely oligomannose antigens. Proceedings of the National Academy of Sciences, 2010; DOI: 10.1073/pnas.1006498107

Cite This Page:

University of Oxford. "HIV's sugar coating offers new vaccine approach." ScienceDaily. ScienceDaily, 27 July 2010. <www.sciencedaily.com/releases/2010/07/100723130141.htm>.
University of Oxford. (2010, July 27). HIV's sugar coating offers new vaccine approach. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2010/07/100723130141.htm
University of Oxford. "HIV's sugar coating offers new vaccine approach." ScienceDaily. www.sciencedaily.com/releases/2010/07/100723130141.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com
$23.6 Billion Awarded To Widow In Smoking Lawsuit

$23.6 Billion Awarded To Widow In Smoking Lawsuit

Newsy (July 20, 2014) Cynthia Robinson claims R.J. Reynolds Tobacco Company hid the health and addiction risks of its products, leading to the death of her husband in 1996. Video provided by Newsy
Powered by NewsLook.com
Tooth Plaque Provides Insight Into Diets Of Ancient People

Tooth Plaque Provides Insight Into Diets Of Ancient People

Newsy (July 19, 2014) Research on plaque from ancient teeth shows that our prehistoric ancestor's had a detailed understanding of plants long before developing agriculture. Video provided by Newsy
Powered by NewsLook.com
Contaminated Water Kills 3 Babies in South African Town

Contaminated Water Kills 3 Babies in South African Town

AFP (July 18, 2014) Contaminated water in South Africa's northwestern town of Bloemhof kills three babies and hospitalises over 500 people. The incident highlights growing fears over water safety in South Africa. Duration: 02:22 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins